The role of human defensins in gastrointestinal diseases

References

• Wehkamp J, Schauber J, Stange EF. Defensins and cathelicidins in gastrointestinal infections. Curr. Opin. Gastroenterol.23, 32–38 (2007).
   Web of Science ®Google Scholar
• Ramasundara M, Leach ST, Lemberg DA, Day AS. Defensins and inflammation: the role of defensins in inflammatory bowel disease. J. Gastroenterol. Hepatol.24, 202–208 (2009).
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Stange EF. Paneth’s disease. J. Crohn’s Colitis4, 523–531 (2010).
   Google Scholar
• Wehkamp J, Stange EF, Fellerman K. Defensin-immunology in inflammatory bowel disease. Gastroenterol. Clin. Biol.33(Suppl. 3), 137–144 (2009).
   Google Scholar
• Wehkamp J, Fellerman K, Herrlinger KR et al. Human β-defensin 2 but not β-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol.14, 745–752 (2002).
   PubMed Web of Science ®Google Scholar
• Fellerman K, Wehkamp J, Herrlinger KR, Stange EF. Crohn’s disease: a defensin deficiency syndrome? Eur. J. Gastroenterol. Hepatol.15, 627–634 (2003).
   Google Scholar
• Salzman NH, Underwood MA, Bevins CL. Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa. Semin. Immunol.19, 70–83 (2007).
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Koslowski M, Wang G, Stange EF. Barrier dysfunction due to distinct defensing deficiencies in small intestinal and colonic Crohn’s disease. Mucosal Immunol.1(1), 67–74 (2008).
   PubMed Web of Science ®Google Scholar
• Langhorst J, Junge A, Rueffer A et al. Elevated human β-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am. J. Gastroenterol.104, 404–410 (2009).
   PubMed Web of Science ®Google Scholar
• Cunliffe RN. α-defensins in the gastrointestinal tract. Mol. Immunol.40, 463–467 (2003).
   PubMedGoogle Scholar
• Voss E, Wehkamp J, Wehkamp K, Stange EF, Schroder JM, Harder J. NOD2/CARD15 mediates induction of the antimicrobial peptide human β-defensin-2. J. Biol. Chem.281, 2005–2011 (2006).
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Harder J, Weichenthal M et al. Inducible and constitutive β-defensins are differentially expressed in Crohn´s disease and ulcerative colitis. Inflamm. Bowel Dis.4, 215–223 (2003).
   Google Scholar
• Ouellette AJ, Hsieh MM, Nosek MT et al. Mouse Paneth cell defensins: primary structures and antibacterial activities of numerous cryptdin isoforms. Infect. Immun.62, 5040–5047 (1994).
   PubMed Web of Science ®Google Scholar
• Selsted ME, Miller SI, Henschen AH et al. Enteric defensins: antibioitic peptide components of intestinal host defense. J. Cell. Biol.118, 929–936 (1992).
   PubMed Web of Science ®Google Scholar
• Harder J, Bartels J, Christophers E et al. A peptide antibiotic from human skin. Nature387, 861 (1997).
   PubMed Web of Science ®Google Scholar
• Harder J, Bartels J, Christophers E et al. Isolation and characterization of human β-defensin-3, a novel human inducible peptide antibiotic. J. Biol. Chem.276, 5707–5713 (2001).
   PubMed Web of Science ®Google Scholar
• Zasloff M. Antibiotic peptides as mediators of innate immunity. Curr. Opin. Immunol.4, 3–7 (1992).
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Salzman NH, Porter E et al. Reduced Paneth cell α-defensins in ileal Crohn’s disease. Proc. Natl Acad. Sci. USA13, 102(50), 18129–18134 (2005).
   Google Scholar
• Wehkamp J, Fellerman K, Stange EF. Human defensins in Crohn’s Disease. A molecular link to mucosal barrier dysfunction. In: Mechanisms of Epithelial Defense (Volume 86). Kabelitz D, Schröder JM (Eds). Karger, Basel, Switzerland, 42–54 (2005).
   Google Scholar
• Schutte BC, Mitros JP, Bartlett JA et al. Discovery of five conserved β-defensin gene clusters using a computational search strategy. Proc. Natl Acad. Sci. USA99, 2129–2133 (2002).
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Schmid M, Stange EF. Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr. Opin. Gastroenterol.23, 370–378 (2007).
   PubMed Web of Science ®Google Scholar
• Ouellette AJ, Bevins CL. Paneth cell defensins and innate immunity of the small bowel. Inflamm. Bowel Dis.7, 43–50 (2001).
   PubMedGoogle Scholar
• Salzman NH, Hung K, Haribhai D et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat. Immunol.11(1), 76–82 (2010).
   PubMed Web of Science ®Google Scholar
• Ayabe T, Satchell DP, Wilson CL et al. Secretion of microbicidal α-defensins by intestinal Paneth cells in response to bacteria. Nat. Immunol.2, 113–118 (2000).
   Google Scholar
• Zhao C, Wang I, Lehrer RI. Widespread expression of β-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett.396(2–3), 319–322 (1996).
   PubMed Web of Science ®Google Scholar
• Lakatos PL, Altorjay I, Mandi Y et al. Interaction between seroreactivity to microbial antigens and genetics in Crohn’s disease: is there a role for defensins? Tissue Antigens71, 552–559 (2008).
   Google Scholar
• Schroeder BO, Wu Z, Nuding SM et al. Reduction of disulphide bonds unmasks potent antimicrobial activity of human β-defensin 1. Nature469, 419–425 (2011).
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Harder J, Wehkamp K et al. NF-κB and AP-1-mediated induction of human β-Defensin-2 in intestinal epithelial cells by Escherichia Coli Nissle 1917: a novel effect of a probiotic bacterium. Infect. Immun.10, 5750–5758 (2004).
   Google Scholar
• Kobayashi T, Okamoto S, Hisamatsu T et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease. Gut57(12), 1682–1689 (2008).
   PubMed Web of Science ®Google Scholar
• Frye M, Bargon J, Lembke B, Wagner TO, Gropp R. Differential expression of human α- and β-defensins mRNA in gastrointestinal epithelia. Eur. J. Clin. Invest.30(8), 695–701 (2000).
   Google Scholar
• Langhorst J, Wieder A, Rueffer A et al. Activated innate immune system in irritable bowel disease? Gut9, 1325–1326 (2007).
   Google Scholar
• O’Neil DA, Porter EM, Elewaut D et al. Expression and regulation of the human β-defensins hBD-1 and hBD-2 in intestinal epithelium. J. Immunol.163(12), 6718–6724 (1999).
   PubMed Web of Science ®Google Scholar
• Sellon RK, Tonkonogy S, Schulz M et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect. Immun.66, 5224–5231 (1998).
   PubMed Web of Science ®Google Scholar
• Zilbauer M, Jenke A, Wenzel G et al. Expression of human β-defensins in children with chronic inflammatory bowel disease. PLoS One5(10), e15389 (2010).
   Google Scholar
• Simms LA, Doecke JD, Walsh MD, Huang N, Fowler EV, Radford-Smith GL. Reduced α-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn’s disease. Gut57, 903–910 (2008).
   PubMed Web of Science ®Google Scholar
• Fellermann K, Stange DE, Schaeffeler E et al. A chromosome 8 gene-cluster polymorphism with low human β-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am. J. Hum. Genetics79, 439–448 (2006).
   PubMed Web of Science ®Google Scholar
• Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature411, 603–606 (2006).
   Google Scholar
• Vavricka SR, Rogler G. New insights into the pathogenesis of Crohn’s disease: are they relevant for therapeutic options? Swiss Med. Wkly139(37–38), 527–534 (2009).
   Google Scholar
• Barreira-de-Acosta M, Mendoza JL, Lana R, Dominguez-Munoz JE, Diaz-Rubio M. NOD2/CARD15: geographic differences in the Spanish population and clinical applications in Crohn’s disease. Rev. Esp. Enferm. Dig.102(5), 321–326 (2010).
   Google Scholar
• Barrett JC, Hansoul S, Nicolae DL et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat. Genet.40, 955–962 (2008).
   PubMed Web of Science ®Google Scholar
• Franke A, Balschun T, Karlsen TH et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat. Genet.40, 1319–1323 (2008).
   PubMed Web of Science ®Google Scholar
• Fisher SA, Tremelling M, Andersen CA et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn’s disease. Nat. Genet.40, 710–712 (2008).
   PubMed Web of Science ®Google Scholar
• Stallmach A, Carstens O. Role of infections in the manifestation or reactivation of inflammatory bowel diseases. Inflamm. Bowel Dis.8, 213–218 (2002).
   PubMed Web of Science ®Google Scholar
• Card T, Logan RFA, Rodrigues LC, Wheeler JG. Antiobiotic use and the development of Crohn’s disease. Gut53, 246–250 (2004).
   PubMed Web of Science ®Google Scholar
• Bernstein CN. Epidemiologic clues to inflammatory bowel disease. Curr. Gastroenterol. Rep.12(6), 495–501 (2010).
   Google Scholar
• Salzman NH, Bevins CL. Negative interactions with the microbiota: IBD. Adv. Exp. Med. Biol.635, 67–78 (2008).
   Google Scholar
• Swidsinski A, Ladhoff A, Pernthaler A et al. Mucosal flora in inflammatory bowel disease. Gastroenterol.122, 44–54 (2002).
   PubMed Web of Science ®Google Scholar
• Nuding S, Fellerman K, Wehkamp J, Stange EF. Reduced mucosal antimicrobial activity in Crohn’s disease of the colon. Gut56, 1240–1247 (2007).
   PubMed Web of Science ®Google Scholar
• Aldhous MC, Noble CL, Satsangi J. Dysregulation of human β-defensin-2 protein in inflammatory bowel disease. PLoS One4(7), e6285 (2009).
   PubMed Web of Science ®Google Scholar
• Hollox EJ. β-Defensins and Crohn’s disease: confusion from counting copies. Am. J. Gastroenterol.105, 360–362 (2010).
   Google Scholar
• Kanda N, Watanabe S. IL-12, IL-23, and IL-27 enhance human β-defensin-2 production in human keratinocytes. Eur. J. Immunol.38(5), 1287–1296 (2008).
   PubMedGoogle Scholar
• Kao CY, Chen Y, Thai P et al. IL-17 markedly up-regulates β-defensin-2 expression in human airway epithelium via JAK and NF-κB signaling pathways. J. Immunol.173(5), 3482–3491 (2004).
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Chu H, Shen B et al. Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues. FEBS Lett.580(22), 5344–5350 (2006).
   PubMed Web of Science ®Google Scholar
• Elphick D, Liddell S, Mahida YR. Impaired luminal processing of human defensin-5 in Crohn’s disease: persistence in a complex with chymotrypsinogen and trypsin. Am. J. Pathol.172, 702–713 (2008).
   PubMed Web of Science ®Google Scholar
• Inohara N, Chamaillard M, McDonald C, Nunez G. NOD-LRR proteins: role in host–microbial interactions and inflammatory disease. Annu. Rev. Biochem.19, 355–383 (2005).
   Google Scholar
• Lala S, Ogura Y, Osborne C et al. Crohn’s disease and the NOD2 gene: a role for paneth cells. Gastroenterol.125, 47–57 (2003).
   PubMed Web of Science ®Google Scholar
• Ogura Y, Lala S, Xin W et al. Crohn’s disease and the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterol.124, 1001–1009 (2003).
   Google Scholar
• Gasche C, Grundtner P. Genotypes and phenotypes in Crohn’s disease: do they help in clinical management? Gut54, 162–174 (2005).
   PubMed Web of Science ®Google Scholar
• Bernard P, Flemin A, Lacombe A, Harley VR, Vilain E. Wnt4 inhibits β-catenin/TCF signalling by redirecting β-catenin to the cell membrane. Biol. Cell.100(3), 167–177 (2008).
   PubMed Web of Science ®Google Scholar
• Simms LA, Doecke JD, Roberts RL et al. KCNN4 gene variant is associated with ileal Crohn’s disease in the Australian and New Zealand population. Am. J. Gastroenterol.105(10), 2209–2217 (2010).
   PubMedGoogle Scholar
• Bentley RW, Pearson J, Gearry RB et al. Association of higher DEFB4 genomic copy number with Crohn’s disease. Am. J. Gastroenterol.105, 354–359 (2010).
   PubMed Web of Science ®Google Scholar
• Fahlgren A, Hammarstrom S, Danielsson A et al. β-Defensin-3 and -4 in intestinal epithelial cells display increased mRNA expression in ulcerative colitis. Clin. Exp. Immunol.137, 397–385 (2003).
   Google Scholar
• Noble CL, Abbas AR, Cornelius J et al. Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis. Gut57(10), 1398–1405 (2008).
   PubMed Web of Science ®Google Scholar
• Möndel M, Schroeder BO, Zimmermann K et al. Probiotic E.coli treatment mediates antimicrobial human β-defensin synthesis and fecal excretion in humans. Mucosal Immunol.2(2), 166–172 (2009).
   PubMed Web of Science ®Google Scholar
• Dinan TG, Quigley EMM, Ahmed SMM et al. Hypothalamic–pituitary–gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterol.130, 304–311 (2006).
   PubMed Web of Science ®Google Scholar
• Thompson WG, Longstreth GF, Drossman DA et al. Functional bowel disorders and functional abdominal pain. Gut45(Suppl. 2), 43–47 (1999).
   Web of Science ®Google Scholar
• Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut47, 804–811 (2000).
   PubMed Web of Science ®Google Scholar
• Dunlop SP, Jenkins D, Neal KR et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterol.125, 1651–1659 (2003).
   PubMed Web of Science ®Google Scholar
• Cumberland P, Sethi D, Roderick PJ et al. The infectious intestinal disease study of England: a prospective evaluation of symptoms and health care use after an acute episode. Epidemiol. Infect.130, 453–460 (2003).
   PubMed Web of Science ®Google Scholar
• Gwee KA, Collins SM, Read NW et al. Increased rectal mucosal expression of interleukin 1β in recently acquired post-infectious irritable bowel syndrome. Gut52, 523–526 (2003).
   PubMed Web of Science ®Google Scholar
• Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am. J. Gastroenterol.95, 3503–3506 (2000).
   PubMed Web of Science ®Google Scholar
• Gwee K. Post-infectious irritable bowel syndrome, an inflammation-immunological model with relevance for other IBS and functional dyspepsia. J. Neurogastroenterol. Motil.16(1), 30–34 (2010).
   PubMedGoogle Scholar
• Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK, Cho SW. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J. Gastroenterol. Hepatol.23(11), 1689–1694 (2008).
   PubMed Web of Science ®Google Scholar
• Chadwick VS, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterol.122(7), 1778–1783 (2002).
   PubMed Web of Science ®Google Scholar
• Guilarte M, Santos J, de Torres I et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut56(2), 203–209 (2007).
   PubMed Web of Science ®Google Scholar
• Ohman L, Isaksson S, Lundgren A, Simrén M, Sjövall H. A controlled study of colonic immune activity and β7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin. Gastroenterol. Hepatol.3(10), 980–986 (2005).
   PubMed Web of Science ®Google Scholar
• Elsenbruch S, Holtmann G, Oezcan D et al. Are there alterations of neuroendocrine and cellular immune responses to nutrients in women with irritable bowel syndrome? Am. J. Gastroenterol.99, 703–710 (2004).
   Google Scholar
• Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut52(1), 91–93 (2003).
   PubMed Web of Science ®Google Scholar
• Van der Veek PP, van den Berg M, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-α and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am. J. Gastroenterol.100(11), 2510–2516 (2005).
   PubMed Web of Science ®Google Scholar